Recombinant antibody expression in mammalian cells is crucial when post-translational modifications and appropriate folding are desired for downstream applications. Commonly, the top challenges of antibody expression projects are: 1) insufficient antibody yield 2) long time to completion, often taking several months 3) budget overruns. To lift up these bottlenecks, GenScript has launched its proprietary TurboCHO™ platform, which offers higher yield performance within a shorter time period. This cost-effective production system enables small to large-scale (microgram to kilogram) antibody production with a high level of consistency, making it an excellent complement for target discovery, pre-evaluation pipelines, and overall providing added value to users.
In addition, GenSmart™ Codon Optimization, an industry-standard free codon optimization tool, facilitates designing your gene sequence to maximize the possibility of obtaining functional antibodies through the TurboCHO™ expression system.
From gene synthesis to protein delivery as fast as 8 BDs
Learn MoreDesigned for high-throughput screening, as fast as 5 BDs
Learn MoreYield up to gram, starts from 10 BDs
Learn MoreYield up to kg, from 6-7 weeks
Learn MoreHigh expression level with ECACC-licensed CHO-K1 cell
Learn MoreSucceed with seamless CHO expression systems, from Start to Finish.
| TurboCHO™ HT
(High Throughput) |
TurboCHO™ Express | TurboCHO™ HP
(High Performance) |
|||||
| Requested Protein Amount | Up to 5 mg | Up to 1000 mg | 1 g to Kilograms | ||||
| Production Time Starting From Gene Synthesis | Starts from 5 BDs | 10 BDs | 6 ~ 7 weeks | ||||
| Deliverables | Target Purity ≥ 90% Target Endotoxin Level ≤ 0.5 EU/mg |
Target Purity: Antibody ≥ 95% ; Protein≥ 90% Target Endotoxin Level ≤ 0.5 EU/mg Target Con. ≥ 1.0 mg/mL |
Target Purity: Antibody≥95%, Protein ≥90% Target Endotoxin Level: ≤1EU/mg Target Con. ≥1.0mg/mL |
||||
| Additional Services |
|
||||||
Note:
This customized solution applies to all types of proteins, antibody species, isotypes, and fragments.
All incoming projects are subjected to evaluation.
Additional QC and characterizations are offered with an extra charge upon request.
Pilot expression evaluation can be requested for CHO-Express/HP.
Case1: Bispecific Antibody Production
Titer: 374 mg/L with Purity > 99%
After purification yield: 65mg/L, Purity (SDS-Page)>95%, Purity (SEC)>93%
After purification yield: 98mg/L, Purity (SDS-Page)>90%, Purity (SEC)>99%
Case 2: Fragment Antibody Production
Titer: 118 mg/L with Purity >
99%
Titer: 169 mg/L with Purity > 99%
Empowered by GenScript’s TurboCHO™ expression system, our high throughput gene to antibody service enables the fastest “Gene to Target” delivery. From sequence to purified antibody, in as short as 10 business days, TurboCHO™ HT cost-effectively expedites the screening of therapeutic targets. Moving along the discovery workflow, the TurboCHO™ Express service provides a better solution for therapeutic lead expression and optimization and diagnostic biomarker discovery. Finally, once the lead is identified, our TurboCHO™ HP stable expression service is designed to support the flow of drugs into clinical evaluation or diagnostic assay development. By implementing an effective mitigation strategy through gram levels of antibody production while keeping a high-quality standard based on comprehensive QC specs, TurboCHO™ HP provides a leading-edge on candidate selection.
Antibody/Protein Therapeutics
Diagnostic
"CHO cells" or Chinese Hamster Ovary cells have a long history as tools for the generation of biological therapeutics (i.e. monoclonal antibodies, enzymes, cytokines, and hormones). CHO cell-derived monoclonal antibodies have been approved to treat a broad range of indications, including cancer, multiple sclerosis, asthma, HIV, and neuroblastoma. Several favorable properties have driven CHO cells' increased use in bioprocessing, including their resilience to growth conditions, resistance to viral infections, and high protein synthesis capacity. Significantly, protein-processing by CHO cells more closely conserves the post-translational modifications (e.g., glycosylation) and folding found in human proteins.
On top of that, consistent use of a specific cell expression system across the early and late biotherapeutic protein development stages is critical. For example, the use of CHO transit expression in therapeutic monoclonal antibody development expedites the availability of smaller quantities of antibody candidates, ideal for preliminary in vitro testing. Higher-yield stable CHO expression of lead recombinant monoclonal antibodies is a recommended path towards later preclinical stages. This approach increases the probability that candidates for pharmacological and toxicological characterization conserve established glycosylation patterns supporting IND and therapeutic development.
Overview of recombinant therapeutic antibody
Host selection for recombinant antibody expression
Why CHO expression system is still the favorable workhorse for recombinant protein production
Learn More
A handbook chapter with detailed protocols and tips for rAb expression.
Free Download Free Download
A white paper with technical advice for optimizing your system for rAb expression.
Free Download Free Download
